Instil Bio, Inc. TIL
5.55 USD +0.12 (+2.21%)
Regular-session close
5.55 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
5.49 Day range 5.77
5.14 52-week range 13.50
- YTD
- -49.55%
- 1 year
- -54.51%
No chart data for this range yet.
- Market cap
- 37.64M
- EPS (ttm)
- -3.09
- Shares out
- 6.53M
- Forward P/E
- -1.80
- YTD return
- -49.55%
- 1-year return
- -54.51%
- 50-day average
- 29.13
- 200-day average
- 20.96
- Enterprise value
- 128.32M
- Volume
- 61.88K
- Avg volume
- 40.24K
- Open
- 5.55
- Previous close
- 5.43
- Day's range
- 5.49 – 5.77
- 52-week range
- 5.14 – 13.50
- Beta
- 1.74
- Analysts
- Buy
- Price target
- 100.33 (+1707.8%)
Key statistics
- Price / book
- 0.63
- Free cash flow
- -27.20M
- Total cash
- 148.77M
- Total debt
- 85.61M
- Return on equity
- -48.65%
- Short % of float
- 10.03%
Fundamental scorecard
4 of 25 checks passed on TIL’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
TIL Revenue — quarterly 0
TIL Net income — quarterly -4.23M
TIL EPS — quarterly -0.62
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -2.08 | -3.54 | -1.46 | -70.19% |
| Aug 13, 2024 | Jun 1, 2024 | -3.04 | -2.29 | +0.75 | +24.67% |
| Aug 13, 2024 | Jun 1, 2024 | -3.04 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -2.16 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -2.16 | -3.74 | -1.58 | -73.15% |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -1.99 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 4, 2024 | JMP Securities | init | — | Market Perform |
| Sep 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 16, 2024 | Baird | reit | Outperform | Outperform |
About Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- instilbio.com
News
Your note
Sign in to keep a note on TIL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Curative Ventures V LLC | 29.10% | 1,899,004 | 41.25M | Sep 29, 2024 |
| Vivo Capital, LLC | 9.57% | 624,339 | 13.56M | Sep 29, 2024 |
| CPMG INC | 6.30% | 410,922 | 8.93M | Sep 29, 2024 |
| Boxer Capital, LLC | 5.45% | 355,500 | 7.72M | Sep 29, 2024 |
| Perceptive Advisors Llc | 5.29% | 345,545 | 7.51M | Sep 29, 2024 |
| BML Capital Management, LLC | 5.13% | 335,000 | 7.28M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.32% | 85,903 | 1.87M | Sep 29, 2024 |
| Invesco Main Street Small Cap Fund | 1.04% | 67,774 | 1.47M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.93% | 60,755 | 1.32M | Sep 29, 2024 |
| Invesco V.I. Main Street Small Cap Fund | 0.48% | 31,570 | 685.70K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.33% | 21,762 | 472.67K | Oct 30, 2024 |
| Massmutual Premier Small Cap Opportunities Fund | 0.22% | 14,439 | 313.62K | Sep 29, 2024 |
